Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: QuietWon who wrote (58239)	2/24/1999 5:25:00 PM
From: Silicon Trader	Respond to of 119973

Hi QuietWon, Well today sure was a wild one coupled with the last couple of weeks. I spent the afternoon researching a word you typed in one of your posts. Although it was interesting i did not have much sucess. Maybe you could help me IMCL - carcked the 10 1/8th Rofl LOL Just having some fun with ya :) I can't type worth a damn when i am trading or any other time for that matter

To: QuietWon who wrote (58239)	2/25/1999 6:19:00 AM
From: blackmerlin	Read Replies (3) \| Respond to of 119973

GMED proves it's gene expression technology with endostatin: QuietWon thank you for your information on IMCL. In the biotech area also take a look at GMED. Recently, a Boston Globe article shows that Genemedicine's gene expression technology may represent a very powerful tool. GMED scientists expressed active endostatin, a protein that has been considered to be very difficult to work with by scientists at Bristol Myers Squibb and the NCI, in the muscle cells of living mice. This is probably an important point of the article - the power of Genemedicine's technology and indicates an edge for the company versus it's competitors. Please see : "Possible cancer inhibitor passes a test" at: boston.com. Another point of the article is that endostatin was active as expressed in living cells in mice. The experiments therefore get around the issues of any possible in vitro stability problems that proteins such as endostatin and angiostatin may or may not have. The above post is for information purposes only and is not an endorsement to buy or sell any stock. The individual investors, as always, should make investment decisions based on the total public information on a particular stock readily available to the investor. Regrads, Blackmerlin